Myosin heavy chain (MHC) consists of a myosin carboxyl terminal rod and an amino terminal globular head that interacts with actin [@bib1], [@bib2]. During contraction, force is transduced via a hinge region between these 2 domains, allowing attachment--detachment of the myosin head with actin filaments. There are 2 cardiac-specific isoforms of MHC: α-cardiac MHC and β-cardiac MHC. In humans, β-MHC predominates in adult life, accounting for \>90% of ventricular myosin [@bib3]. Genetic mutations in contractile protein β-MHC account for approximately 40% of genotyped families with hypertrophic cardiomyopathy (HCM) [@bib4], [@bib5], [@bib6].

The human β-MHC mutation *MYH7 Arg403Gln* causes a severe form of HCM characterized by early-onset and progressive myocardial dysfunction with a high incidence of sudden cardiac death [@bib7]. However, the relationship between the gene mutation and phenotype is poorly understood.

Heterozygous mice expressing the human disease--causing mutation *Arg403Gln* (*αMHC*^*403/+*^) exhibit hallmark features of the cardiomyopathy, including hypertrophy, myocyte disarray, and increased myocardial fibrosis [@bib8]. We have previously demonstrated that treatment of *αMHC*^*403/+*^ mice with the L-type calcium channel (I~Ca-L~) antagonist diltiazem decreases left ventricular anterior wall thickness, cardiac myocyte hypertrophy, disarray, and fibrosis [@bib9], [@bib10]. In addition, administration of diltiazem to patients with HCM improves left ventricular end-diastolic diameter and left ventricular wall thickness-to-dimension ratio [@bib10]. However, the role of I~Ca-L~ in development of the cardiomyopathy is currently unknown.

The cytoskeleton consists of microtubules composed of tubulin, microfilaments composed of actin, and intermediate filaments, and is recognized as a modulator of cell morphology, motility, intracytoplasmic transport, and mitosis [@bib11], [@bib12]. Cytoskeletal proteins also regulate the function of proteins in the plasma membrane [@bib13], [@bib14]. I~Ca-L~ is anchored to F-actin and β-tubulin that regulate I~Ca-L~ activation and inactivation kinetics [@bib15], [@bib16], [@bib17], [@bib18]. In addition, the mitochondrial outer membrane contains docking sites for cytoskeletal proteins that can regulate mitochondrial function [@bib12], [@bib19], [@bib20].

Calcium influx through the I~Ca-L~ or dihydropyridine channel is critical to cardiac excitation and contraction. I~Ca-L~ can also regulate mitochondrial function. Activation of I~Ca-L~ with voltage clamp of the plasma membrane or with application of the dihydropyridine receptor agonist Bay K8644 (BayK(-)) is sufficient to increase cytosolic and mitochondrial calcium, in addition to NADH production, superoxide generation, and metabolic activity in a calcium-dependent manner [@bib21], [@bib22]. Activation of I~Ca-L~ can also increase mitochondrial membrane potential (Ψ~m~) in a calcium-independent manner [@bib21]. The response is reversible upon inactivation of I~Ca-L~ and is in part dependent on F-actin filaments because depolymerization of F-actin prevents the response [@bib21]. The beta subunit (β~2~) of I~Ca-L~ is tethered to cytoskeletal proteins. Preventing movement of the β~2~ subunit with application of a peptide derived against the alpha-interacting domain of I~Ca-L~ attenuates the increase in Ψ~m~ [@bib21]. Therefore, I~Ca-L~ influences metabolic activity through transmission of movement of I~Ca-L~ via cytoskeletal proteins.

We and others have demonstrated that *αMHC*^*403/+*^ mice exhibit increased actin--myosin sliding velocity, force generation, increased ATPase activity, and ADP concentration [@bib23], [@bib24]. Here, we sought to identify whether the *Arg403Gln* mutation leads to mitochondrial dysfunction in cardiac myocytes isolated from 30- to 50-week-old *αMHC*^*403/+*^ mice with established cardiomyopathy [@bib8], [@bib25]. Specifically, we investigated whether the mutation resulted in altered communication between the I~Ca-L~ and mitochondria, and subsequently, altered metabolic activity.

Methods {#sec1}
=======

Mouse models {#sec1.1}
------------

Male 30- to 50-week-old and 10- to 15-week-old mice expressing the human disease--causing mutation *Arg403Gln* (*αMHC*^*403/+*^) were generated [@bib8] and studied. The mice develop cardiomyopathy by 30 to 50 weeks as evidenced by echocardiography and heart weight to body weight measurements ([Supplemental Table 1](#appsec1){ref-type="sec"}). Genotype-negative littermate age-matched male mice were used as wild-type (*wt*) controls. Hearts were extracted as approved by The Animal Ethics Committee of The University of Western Australia in accordance with the *Australian Code of Practice for the Care and Use of Animals for Scientific Purposes* (NH&MRC, 8th Edition, 2013). Cardiac myocytes were isolated as previously described [@bib26], [@bib27]. Detailed methods are provided in the [Supplemental Methods](#appsec1){ref-type="sec"}.

Data acquisition for patch clamp studies {#sec1.2}
----------------------------------------

Whole-cell configuration of the patch clamp technique was used to measure changes in I~Ca-L~ currents in intact cardiac myocytes as described previously [@bib28], [@bib29]. Detailed methods are provided in the [Supplemental Methods](#appsec1){ref-type="sec"}.

Fluorescent studies {#sec1.3}
-------------------

All studies were performed in intact mouse cardiac myocytes at 37°C as previously described. Intracellular calcium (\[Ca^2+^\]~i~) was monitored using Fura-2 [@bib29]. Superoxide generation was assessed using dihydroethidium [@bib29]. Fluorescent indicator JC-1 was used to measure Ψ~m~ [@bib29]. Flavoprotein autofluorescence was used to measure flavoprotein oxidation [@bib30]. Detailed methods are provided in the [Supplemental Methods](#appsec1){ref-type="sec"}.

MTT assay {#sec1.4}
---------

The rate of cleavage of the tetrazolium salt MTT to formazan by the mitochondrial electron transport chain was measured spectrophotometrically as previously described [@bib21], [@bib26]. Detailed methods are provided in the [Supplemental Methods](#appsec1){ref-type="sec"}.

Mitochondrial respiration studies and DNA copy number {#sec1.5}
-----------------------------------------------------

Mitochondrial respiration was measured in mitochondria isolated from 3 pooled *wt* and 3 pooled *αMHC*^*403/+*^ mouse hearts at 37°C as previously described [@bib31]. Detailed methods are provided in the [Supplemental Methods](#appsec1){ref-type="sec"}. Mitochondrial DNA copy number was determined by quantitative reverse-transcription polymerase chain reaction as previously described [@bib32].

Quantitative reverse-transcription polymerase chain reaction {#sec1.6}
------------------------------------------------------------

Transcript abundance of mitochondrial transcription factor A (TFAM), peroxisome proliferator-activated receptor gamma (PPARγ) and peroxisome proliferator-activated receptor gamma coactivator (PGC)-1 was measured as previously described [@bib33]. Detailed methods are provided in the [Supplemental Methods](#appsec1){ref-type="sec"}.

Sample preparation for transmission electron microscopy and confocal imaging {#sec1.7}
----------------------------------------------------------------------------

For transmission electron microscopy, cardiac tissue samples were imaged on a JEOL JEM-2100 electron microscope (JEOL, Akishima, Japan). For confocal imaging, cardiac myocytes tripled stained with MitoTracker (mitochondria), phalloidin (F-actin) and DAPI (nuclei) (Thermo Fisher Scientific, Massachusetts) were imaged on an Olympus IX71 inverted fluorescent microscope (Olympus, Tokyo, Japan).

Detailed methods are provided in the [Supplemental Methods](#appsec1){ref-type="sec"}.

Statistical analysis {#sec1.8}
--------------------

Results are reported as mean ± SEM or SD where indicated. Statistical comparisons of parametric data were made using the unpaired Student *t* test (GraphPad Prism version 5.04, GraphPad Software, La Jolla, California). Statistical comparisons of non-parametric data were made using the Mann-Whitney U test, or Kruskal-Wallis test (GraphPad Prism version 5.04).

Results {#sec2}
=======

*αMHC*^*403/+*^ cardiac myocytes exhibit altered I~Ca-L~ inactivation kinetics {#sec2.1}
------------------------------------------------------------------------------

Using the patch clamp technique, we measured I~Ca-L~ currents in *αMHC*^*403/+*^ myocytes ([Figure 1A](#fig1){ref-type="fig"}). We found no difference in I~Ca-L~ current density recorded in *αMHC*^*403/+*^ versus *wt* myocytes (*αMHC*^*403/+*^ 3.86 ± 0.26 pA/pF vs. *wt* 3.91 ± 0.30, p = NS) ([Figures 1C and 1F](#fig1){ref-type="fig"}). These data suggest that I~Ca-L~ expression is not altered in *αMHC*^*403/+*^ myocytes. To further confirm this, we probed immunoblots of I~Ca-L~ protein isolated from *αMHC*^*403/+*^ hearts with an antibody directed against the pore-forming α~1C~ subunit. Densitometry analysis indicated a slight increase (8.2 ± 0.6%) in α~1C~ subunit expression in *αMHC*^*403/+*^ hearts ([Supplemental Figures 1A and 1B](#appsec1){ref-type="sec"}), but this did not appear to be sufficient to increase peak inward current and current density ([Figures 1A, 1C, and 1F](#fig1){ref-type="fig"}). However, inactivation of the current was significantly faster in *αMHC*^*403/+*^ versus *wt* myocytes (*αMHC*^*403/+*^: τ1 = 32.76 ± 1.96 versus *wt*: τ1 = 40.68 ± 2.49, p \< 0.05) ([Figure 1B](#fig1){ref-type="fig"}). Similar results were obtained when barium was used as the charge carrier indicating that changes in calcium were not mediating alterations in current inactivation ([Figures 1H to 1J](#fig1){ref-type="fig"}). The total integral of current in *αMHC*^*403/+*^ myocytes were significantly less compared with *wt* myocytes, whereas no difference in activation integral was observed ([Figures 1D and 1E](#fig1){ref-type="fig"}). No difference in steady-state inactivation was observed in *αMHC*^*403/+*^ versus *wt* myocytes ([Figure 1G](#fig1){ref-type="fig"}). Consistent with our results indicating no difference in I~Ca-L~ current density or peak inward current in *αMHC*^*403/+*^ myocytes, we found no difference in intracellular calcium (\[Ca^2+^\]~i~) in *αMHC*^*403/+*^ versus *wt* myocytes ([Supplemental Figures 2A to 2C](#appsec1){ref-type="sec"}).Figure 1Myocytes Isolated From *αMHC*^*403/+*^ Hearts Exhibit Altered Inactivation Kinetics**(A)** Representative I~Ca-L~ current traces from *αMHC*^*403/+*^ (130 pF) and wild-type (*wt*) (120 pF) myocytes. **(Inset)** Pulse protocol. **(B)** Mean ± SEM rate of inactivation (tau) of current for *αMHC*^*403/+*^ and *wt* myocytes fitted with 2 exponential functions (*i*, τ 1; and *ii*, τ 2). Mean ± SEM of **(C)** current density, and **(D)** activation integral and **(E)** total integral of current for *αMHC*^*403/+*^ and *wt* myocytes. **(F)** Current/voltage (I--V) relationship and **(G)** voltage dependency of steady-state inactivation measured in *αMHC*^*403/+*^ and *wt* myocytes. **(Insets)** Pulse protocols. **(H)** Representative I~Ca-L~ current traces recorded from *αMHC*^*403/+*^ (100 pF) and *wt* (100 pF) with barium as charge carrier. **(Inset)** Pulse protocol. **(I)** Mean ± SEM of inactivation (tau) of current for *αMHC*^*403/+*^ and *wt* myocytes fitted with 2 exponential functions with barium as charge carrier (*i*, τ 1; and *ii*, τ 2). **(J)** Mean ± SEM of current density for all myocytes with barium as charge carrier. The unpaired Student *t* test was used for comparisons in **B and C**; Mann-Whitney test was used for comparisons in **D to G and I to J**.

The β~2~ subunit of I~Ca-L~ is bound to the α~1C~ subunit of I~Ca-L~ and plays an important role in I~Ca-L~ kinetics [@bib34]. We probed immunoblots of I~Ca-L~ protein with an antibody directed against the β~2~ subunit. No significant alteration in β~2~ subunit expression was observed in *αMHC*^*403/+*^ versus *wt* hearts ([Supplemental Figures 1C and 1D](#appsec1){ref-type="sec"}). Because the β~2~ subunit of I~Ca-L~ is tethered to F-actin filaments that also tightly regulate the function of I~Ca-L~ [@bib15], [@bib16], [@bib17], these data suggest that cytoskeletal architecture rather than altered α~1C~ subunit or β~2~ subunit expression may be responsible for altered inactivation of I~Ca-L~ current in *αMHC*^*403/+*^ myocytes.

*αMHC*^*403/+*^ cardiac myocytes exhibit a significantly larger increase in Ψ~m~ following activation of I~Ca-L~ {#sec2.2}
----------------------------------------------------------------------------------------------------------------

Increased mitochondrial Ca^2+^ uptake is associated with an increase in Ψ~m~. However, Ψ~m~ can function independently of changes in \[Ca^2+^\]~i~ in the range of 0 to 400 nmol/l [@bib35]. We have previously shown that adult guinea pig cardiac myocytes exhibit increased Ψ~m~ following activation of I~Ca-L~ under calcium-free conditions [@bib21]. The response is dependent upon an intact cytoskeletal architecture [@bib21].

Here, we find that application of BayK(-) elicits a significant increase in Ψ~m~ in *αMHC*^*403/+*^ and *wt* myocytes pre-incubated in calcium-free and EGTA containing HEPES-Buffered Solution for at least 3 hours (assessed as changes in JC-1 fluorescence) ([Figures 2A to 2C](#fig2){ref-type="fig"}). The responses were similar to those recorded in 2.5 mmol/l calcium containing Hepes-Buffered Solution ([Supplemental Figure 3A](#appsec1){ref-type="sec"}). However the ratio of the response was significantly larger in *αMHC*^*403/+*^ versus *wt* myocytes ([Figure 2D](#fig2){ref-type="fig"}). The responses could be prevented with application of I~Ca-L~ antagonists nisoldipine or diltiazem ([Figures 2A to 2C](#fig2){ref-type="fig"}). Application of BayK(+) did not significantly alter Ψ~m~ in *αMHC*^*403/+*^ or *wt* myocytes ([Figures 2A to 2C](#fig2){ref-type="fig"}). Sodium cyanide was added to collapse Ψ~m~ demonstrating that the signal was mitochondrial and indicative of Ψ~m~ ([Figures 2A and 2B](#fig2){ref-type="fig"}). No difference was observed in basal Ψ~m~ in *αMHC*^*403/+*^ versus *wt* myocytes ([Supplemental Figures 3B and 3C](#appsec1){ref-type="sec"}). These data demonstrate that activation of I~Ca-L~ causes a significantly greater increase in Ψ~m~ in myocytes isolated from *αMHC*^*403/+*^ hearts compared with *wt* myocytes, and the response does not require calcium.Figure 2*αMHC*^*403/+*^ Cardiac Myocytes Exhibit a Significantly Larger Increase in Ψ~m~ Following Activation of I~Ca-L~Representative ratiometric JC-1 fluorescence recorded in **(A)***wt* myocytes and **(B)***αMHC*^*403/+*^ myocytes before and after exposure to 10 μmol/l BayK(+) or BayK(-) ± 15 μM nisoldipine (Nisol) or diltiazem (Dilt) under calcium-free conditions (0 mmol/l Ca^2+^). **Arrow** indicates addition of drugs. NaCN: 40 mmol/l sodium cyanide. **(C)** Mean ± SEM of JC-1 fluorescence for all myocytes exposed to BayK(+), BayK(-), Nisol, Dilt, 5 μmol/l latrunculin A (Latrunc), or 1 μmol/l colchicine (Colch) as indicated. Latrunc and Colch were added 20 min and 3.5 h before commencing basal Ψ~m~ recording, respectively. **(D)** Ratio of increase in JC-1 fluorescence after addition of BayK(-). The Kruskal-Wallis test was used for all comparisons. I~Ca-L~ = L-type Ca^2+^ channel.

The β~2~ subunit of I~Ca-L~ is tethered to F-actin via subsarcolemmal stabilizing protein AHNAK [@bib15]. Mitochondria also associate with F-actin via mitochondrial docking proteins [@bib36], [@bib37], [@bib38]. We have previously demonstrated that I~Ca-L~ regulates mitochondrial function due to an association between I~Ca-L~ and the mitochondria via cytoskeletal protein F-actin [@bib21], [@bib26]. We exposed *αMHC*^*403/+*^ myocytes to F-actin depolymerizing agent latrunculin A. Under calcium-free conditions, the increase in Ψ~m~ in response to BayK(-) was attenuated in *αMHC*^*403/+*^ and *wt* myocytes ([Figure 2C](#fig2){ref-type="fig"}). These data indicate that elevated Ψ~m~ in response to activation of I~Ca-L~ is dependent on cytoskeletal protein F-actin.

Regulation of Ψ~m~ is in part dependent on the mitochondrial voltage-dependent anion channel (VDAC) [@bib39], [@bib40]. We have previously demonstrated that directly blocking VDAC (and anion transport from the outer mitochondrial membrane) mimics the effect of BayK(-) on Ψ~m~ in *wt* mouse myocytes [@bib26], [@bib41]. In addition, it is known that the cytoskeletal protein β-tubulin associates with and regulates the function of VDAC [@bib42]. Therefore, we examined whether BayK(-)--induced alterations in Ψ~m~ were dependent upon β-tubulin in *αMHC*^*403/+*^ myocytes by incubating myocytes in the β-tubulin depolymerizing agent colchicine. Under calcium-free conditions, the increase in Ψ~m~ in response to BayK(-) was attenuated in *αMHC*^*403/+*^ and *wt* myocytes ([Figure 2C](#fig2){ref-type="fig"}). These data indicate that the increase in Ψ~m~ in response to activation of I~Ca-L~ is dependent on cytoskeletal protein β-tubulin.

*αMHC*^*403/+*^ cardiac myocytes exhibit a significantly larger increase in metabolic activity in response to activation of I~Ca-L~ {#sec2.3}
-----------------------------------------------------------------------------------------------------------------------------------

Metabolic activity is dependent upon oxygen consumption and electron flow down the inner mitochondrial membrane. Application of BayK(-) elicited a significant increase in metabolic activity in both *αMHC*^*403/+*^ and *wt* myocytes ([Figures 3A and 3B](#fig3){ref-type="fig"}). However, the ratio of the response was significantly larger in *αMHC*^*403/+*^ versus *wt* myocytes ([Figure 3C](#fig3){ref-type="fig"}). Both responses could be prevented with application of nisoldipine or the mitochondrial Ca^2+^ uniporter inhibitor Ru360, but not ryanodine ([Figure 3B](#fig3){ref-type="fig"}). Application of BayK(+) did not significantly alter metabolic activity in *αMHC*^*403/+*^ or *wt* myocytes ([Figures 3A and 3B](#fig3){ref-type="fig"}). Application of ATP synthase blocker oligomycin significantly decreased metabolic activity in *αMHC*^*403/+*^ and *wt* myocytes confirming the cells were metabolically active ([Figure 3B](#fig3){ref-type="fig"}).Figure 3*αMHC*^*403/+*^ Cardiac Myocytes Exhibit a Significantly Larger Increase in Metabolic Activity in Response to Activation of I~Ca-L~**(A)** Formation of formazan measured as change in absorbance in *wt* and *αMHC*^*403/+*^ myocytes after addition of 10 μmol/l BayK(+) or BayK(-). **(B)** Mean ± SEM of increases in absorbance for all myocytes exposed to BayK(+), BayK(-), 10 μmol/l nisoldipine (Nisol), 5 μmol/l Ru360, 5 μmol/l ryanodine (RyR), or 20 μmol/l oligomycin (Oligo) as indicated. **(C)** Ratio of increase in absorbance after addition of BayK(-). The Kruskal-Wallis test was used for all comparisons. Abbreviations as in [Figure 1](#fig1){ref-type="fig"}, [Figure 2](#fig2){ref-type="fig"}.

We examined changes in mitochondrial electron transport by measuring alterations in flavoprotein oxidation in myocytes isolated from *αMHC*^*403/+*^ hearts in response to activation of I~Ca-L~. Application of BayK(-) caused a significant increase in flavoprotein oxidation in *αMHC*^*403/+*^ and *wt* myocytes ([Figures 4A to 4C](#fig4){ref-type="fig"}). The ratio of the increase in flavoprotein oxidation was significantly larger in *αMHC*^*403/+*^ versus *wt* myocytes ([Figure 4D](#fig4){ref-type="fig"}). Both responses could be prevented with application of nisoldipine ([Figure 4C](#fig4){ref-type="fig"}). Application of BayK(+) did not significantly alter flavoprotein oxidation in *αMHC*^*403/+*^ or *wt* myocytes ([Figures 4A to 4C](#fig4){ref-type="fig"}). FCCP (carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone) was added at the end of each experiment to increase flavoprotein signal confirming the signal was mitochondrial in origin ([Figures 4A to 4C](#fig4){ref-type="fig"}). These data indicate that activation of I~Ca-L~ causes a significantly greater increase in metabolic activity in myocytes isolated from *αMHC*^*403/+*^ compared to *wt* hearts.Figure 4*αMHC*^*403/+*^ Cardiac Myocytes Exhibit a Significantly Larger Increase In Flavoprotein Oxidation in Response to Activation of I~Ca-L~Representative traces of flavoprotein fluorescence recorded in **(A)***wt* and **(B)***αMHC*^*403/+*^ myocytes before and after exposure to 10 μmol/l BayK(-) or BayK(+). **Arrow** indicates addition of drugs. **(C)** Mean ± SEM of flavoprotein fluorescence for all myocytes exposed to BayK(+), BayK(-), 15 μmol/l nisoldipine (Nisol), or 50 μmol/l FCCP as indicated. **(D)** Ratio of increase in flavoprotein fluorescence after addition of BayK(-). The Kruskal-Wallis test was used for all comparisons. Abbreviations as in [Figure 1](#fig1){ref-type="fig"}, [Figure 2](#fig2){ref-type="fig"}.

Respiratory complex activity is similar in mitochondria isolated from hearts of *αMHC*^*403/+*^ and *wt* hearts {#sec2.4}
---------------------------------------------------------------------------------------------------------------

We performed respiratory electron transport chain complex activity and oxygen consumption measurements on mitochondria isolated from *αMHC*^*403/+*^ and *wt* hearts. No differences were observed in mitochondria isolated from *αMHC*^*403/+*^ versus *wt* hearts ([Figure 5A](#fig5){ref-type="fig"}). These data suggest that alterations in mitochondrial function observed in *αMHC*^*403/+*^ myocytes were cell intrinsic, and not secondary to hypertrophic remodeling of the ventricle.Figure 5Respiration Is Normal, but Gene Expression Is Altered in Mitochondria Isolated From *αMHC*^*403/+*^ Hearts**(A)** Respiration and mitochondrial electron transport chain complex activity in mitochondria isolated from 3 pooled *wt* and 3 pooled *αMHC*^*403/+*^ hearts. **(B)** Mean ± SD of MtDNA copy number normalized to 18S rDNA. **(C)** Mean ± SD of gene expression of *αMHC*^*403/+*^ MtDNA copy number regulators TFAM, PPARγ and PGC1 relative to *wt*. **(D)** Mean ± SD of FGF21. **(E and F)** Representative TEM images demonstrating disordered distribution of mitochondria in *αMHC*^*403/+*^**(F)** versus *wt***(E)** heart sections. M = mitochondria; S = sarcomere. Scale = 1 μm. **(G and H)** Confocal imaging demonstrating disordered mitochondrial distribution and disorganization of F-actin in representative *αMHC*^*403/+*^**(H)** versus *wt***(G)** myocytes. Mitochondria shown in **red** (MitoTracker), F-actin shown in **green** (phalloidin), nuclei shown in **blue** (DAPI). Scale = 10 μm. The Mann-Whitney test was used for all comparisons. MtDNA = mitochondrial DNA; TEM = transmission electron microscopy; *wt* = wild type.

Mitochondrial DNA copy number and gene expression are altered in *αMHC*^*403/+*^ hearts {#sec2.5}
---------------------------------------------------------------------------------------

We found that mitochondrial DNA copy number was increased in *αMHC*^*403/+*^ versus *wt* hearts ([Figure 5B](#fig5){ref-type="fig"}). This correlated with increased expression of nuclear encoded regulators of the mitochondrial genome TFAM, PPARγ, and PGC-1 ([Figure 5C](#fig5){ref-type="fig"}). Because fibroblast growth factor 21 (FGF21) is a marker for mitochondrial dysfunction in myocytes [@bib43], [@bib44], we measured FGF21 in circulating blood from the mice. We measured a significant increase in FGF21 levels in *αMHC*^*403/+*^ versus *wt* mice, correlating with the onset of cardiomyopathy ([Figure 5D](#fig5){ref-type="fig"}). Transmission electron microscopy imaging revealed disordered mitochondrial distribution in *αMHC*^*403/+*^ versus *wt* hearts ([Figures 5E and 5F](#fig5){ref-type="fig"}). Additionally, confocal imaging revealed disordered mitochondrial distribution and disorganization of F-actin in *αMHC*^*403/+*^ versus *wt* myocytes ([Figures 5G and 5H](#fig5){ref-type="fig"}).

Pre-cardiomyopathic *αMHC*^*403/+*^ cardiac myocytes exhibit altered I~Ca-L~ inactivation kinetics and larger increases in Ψ~m~ and metabolic activity following activation of I~Ca-L~ {#sec2.6}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We assessed alterations in I~Ca-L~ inactivation kinetics and mitochondrial responses in cardiac myocytes from 10- to 15-week-old *αMHC*^*403/+*^ hearts that had not yet developed cardiomyopathy ([Supplemental Table 1](#appsec1){ref-type="sec"}) [@bib8], [@bib25]. Using the patch clamp technique, we measured I~Ca-L~ currents in the myocytes ([Supplemental Figure 4A](#appsec1){ref-type="sec"}). Similar to 30- to 50-week-old myocytes, we found no difference in I~Ca-L~ current density in 10- to 15-week-old *MHC*^*403/+*^ versus age-matched *wt* myocytes ([Supplemental Figure 4C](#appsec1){ref-type="sec"}). However, inactivation of the current was significantly faster in *αMHC*^*403/+*^ myocytes ([Supplemental Figure 4B](#appsec1){ref-type="sec"}). Additionally, application of BayK(-) elicited a significantly larger increase in Ψ~m~ and flavoprotein oxidation in 10- to 15-week-old *MHC*^*403/+*^ versus age-matched *wt* myocytes ([Supplemental Figure 5](#appsec1){ref-type="sec"}). The responses could be prevented with I~Ca-L~ antagonist nisoldipine. These data suggest that altered communication between I~Ca-L~ and the mitochondria *precedes* the development of *αMHC*^*403/+*^ cardiomyopathy.

Discussion {#sec3}
==========

The L-type Ca^2+^ channel plays an important role in cardiac excitation and contraction. It can also influence metabolic activity through transmission of movement of the β subunit *via* cytoskeletal proteins [@bib21], [@bib26]. We investigated whether the *Arg403Gln* mutation in contractile protein β-MHC results in impaired communication between I~Ca-L~ and the mitochondria, and subsequently, altered metabolic function. We find that I~Ca-L~ current inactivates more rapidly in myocytes from *αMHC*^*403/+*^ hearts ([Figure 1](#fig1){ref-type="fig"}). This appears to occur as a result of tethering of I~Ca-L~ to cytoskeletal proteins, and is consistent with findings that dissociation of microtubules or depolymerization of actin alters I~Ca-L~ inactivation rate [@bib16], [@bib17], [@bib45], [@bib46]. Peak inward current, current density, and I~Ca-L~ expression were not significantly altered in *αMHC*^*403/+*^ myocytes. Consistent with this, basal and BayK(-)--stimulated increases in \[Ca^2+^\]~i~ and superoxide production were also no different from *wt* myocytes ([Supplemental Figure 2](#appsec1){ref-type="sec"}). Previous studies have demonstrated that the relaxation rate of *αMHC*^*403/+*^ cardiac myocytes is slowed and calcium transients are smaller due to reduced expression of ryanodine receptors and calsequestrin, leading to diminished sarcoplasmic reticulum stores [@bib9], [@bib47]. Taken together, the findings demonstrate that the *Arg403Gln* mutation is associated with altered sarcoplasmic reticulum calcium cycling but does not appear to be associated with significant changes in diastolic Ca^2+^ or superoxide production in aged *αMHC*^*403/+*^ hearts.

One factor that influences metabolic activity and mitochondrial ATP production is electron flow down the inner mitochondrial membrane. We demonstrate that *αMHC*^*403/+*^ cardiac myocytes exhibit a significantly larger increase in Ψ~m~, oxygen consumption and flavoprotein oxidation in response to activation of I~Ca-L~ that can be attenuated by I~Ca-L~ antagonist nisoldipine ([Figure 2](#fig2){ref-type="fig"}, [Figure 3](#fig3){ref-type="fig"}, [Figure 4](#fig4){ref-type="fig"}). The increase in Ψ~m~ can also be attenuated by diltiazem. These data indicate that metabolic activity in *αMHC*^*403/+*^ myocytes is higher versus *wt* myocytes. We demonstrate that this is dependent upon the *intact* cellular environment because respiration was normal in mitochondria isolated from *αMHC*^*403/+*^ hearts ([Figure 5A](#fig5){ref-type="fig"}). In support of this, desmin-null mice exhibit normal rates of maximal respiration in isolated mitochondria, but in vivo mitochondrial respiration is abnormal [@bib20]. Because alterations in mitochondrial function are observed only in the intact myocyte, we conclude that alterations to the cell's intrinsic environment (as evidenced in [Figures 5G and 5H](#fig5){ref-type="fig"}) result in altered communication between I~Ca-L~ and mitochondria, contributing to a hypermetabolic state in the *αMHC*^*403/+*^ cardiac myocyte.

We have demonstrated previously that I~Ca-L~ co-immunoprecipitates with many cytoskeletal proteins [@bib21], [@bib26]. We investigated how the mutation in the MHC gene leads to alterations in protein- protein interactions through the cytoskeletal network. The β~2~ subunit of the L-type Ca^2+^ channel is tightly bound to the α~1C~ subunit via the alpha-interacting domain [@bib48], [@bib49]. The β~2~ subunit of the channel is also tethered to F-actin via subsarcolemmal stabilizing protein AHNAK [@bib15]. Mitochondria also associate with actin via mitochondrial docking proteins [@bib36], [@bib37], [@bib38], and with β-tubulin via VDAC [@bib42]. Here, we demonstrate that elevated Ψ~m~ in response to activation of I~Ca-L~ is dependent on cytoskeletal proteins F-actin and β-tubulin in the *αMHC*^*403/+*^ cardiac myocyte because exposure of myocytes to either F-actin depolymerizing agent latrunculin A or β-tubulin depolymerizing agent colchicine attenuates elevated Ψ~m~ in response to activation of I~Ca-L~ ([Figure 2C](#fig2){ref-type="fig"}). These data indicate that the *Arg403Gln* mutation is associated with altered functional communication between I~Ca-L~ and mitochondria via the cytoskeletal network, and increased cardiac metabolic activity.

To determine whether alterations in mitochondrial responses occurred before the onset of cardiomyopathy, we examined I~Ca-L~ kinetics and the effect of activation of I~Ca-L~ on Ψ~m~ and flavoprotein oxidation in myocytes isolated from pre-cardiomyopathic 10- to 15-week-old *αMHC*^*403/+*^ hearts. Similar responses were recorded to those observed in myocytes from 30- to 50-week-old *αMHC*^*403/+*^ hearts that had developed cardiomyopathy ([Supplemental Figures 4 and 5](#appsec1){ref-type="sec"}). Because the responses were observed before the development of the cardiomyopathy, we conclude that altered communication between the I~Ca-L~ and mitochondria may contribute to the histology and pathophysiology, specifically altered energy reserve and hypercontractility, which has been identified in patients with HCM [@bib50]. The I~Ca-L~ antagonist diltiazem is effective in preventing the development of cardiomyopathy in *αMHC*^*403/+*^ mice and in some patients with identified *MYH7* gene mutations. Our findings indicate that targeting I~Ca-L~ may be effective in the treatment of cardiomyopathy by modulating the activity of the I~Ca-L~ and decreasing/restoring metabolic activity. We speculate that early intervention involving treatment with I~Ca-L~ antagonist diltiazem may prove beneficial in regulating metabolic activity and subsequently, preventing the development of cardiomyopathy in "at-risk" patients with identified *MYH7* gene mutations.Perspectives**COMPETENCY IN MEDICAL KNOWLEDGE:** Mutations in contractile protein β-myosin heavy chain account for approximately 40% of genotyped families with HCM. Altered energy reserve has been identified in patients with HCM, however the relationship between the gene mutation and phenotype is poorly understood. L-type Ca^2+^ channel antagonists are used clinically to treat patients but the role of the L-type Ca^2+^ channel in the development of the cardiomyopathy is unknown. Here we find that the β-myosin heavy chain mutation *Arg403Gln* leads to altered functional communication between the L-type Ca^2+^ channel and mitochondria that is associated with increased cardiac metabolic activity. This may contribute to the development of the cardiomyopathy because the response is present *prior* to the development of cardiomyopathy.**TRANSLATIONAL OUTLOOK:** Further studies are needed to determine cardiac metabolic activity in "at risk" patients with identified *MYH7* gene mutations before the development of HCM. On the basis of our findings, we speculate that utilizing L-type Ca^2+^ channel antagonists as a means of modulating cardiac metabolic activity may prove beneficial in early intervention and subsequent prevention of HCM in at-risk patients with identified *MYH7* gene mutations.
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